Order before 3pm, dispatched same day
Order before 3pm, dispatched same day Research Use Only
Pay by Card / Apple Pay
99% Purity Money Back Guarantee Retatrutide Now Available

BPC-157: Injury Recovery & Tissue Healing Research Overview

Back to library
peptide

BPC-157: Injury Recovery & Tissue Healing Research Overview

8 min read
Tissue Research
BPC-157
Mechanism of Action
Last Updated: May 2026

BPC-157 is a 15-amino acid synthetic peptide derived from a partial sequence of Body Protection Compound found in human gastric juice, and it has accumulated one of the most extensive preclinical research profiles of any research peptide — spanning tendon, ligament, bone, muscle, gut, and vascular tissue models in published literature. The compound’s mechanism involves upregulation of growth factor receptors, activation of the nitric oxide system, stimulation of angiogenesis via VEGF, and direct collagen synthesis promotion — a multi-pathway tissue repair profile that has made it a high-priority research compound in orthopaedic, gastroenterological, and wound healing research. Pure Grade Labs supplies research-grade BPC-157 10mg at 99%+ HPLC-verified purity with batch-specific COA on every order. For research purposes only. Not for human consumption.

Key Takeaways

  • BPC-157 is a 15-amino acid gastric peptide with multi-tissue research applications: Partial sequence of Body Protection Compound from human gastric juice (CAS: 137525-51-0; MW: 1419.55 Da). Published research across tendon, ligament, bone, gut, muscle, and vascular tissue models.
  • Primary mechanisms: NO system upregulation, VEGF-driven angiogenesis, growth factor receptor modulation: BPC-157 activates the eNOS/NO pathway, upregulates VEGF expression (driving new blood vessel formation to injured tissue), and modulates EGF receptor signalling in tissue repair models.
  • Over 30 years of published Sikiric group research: Professor Predrag Sikiric at the University of Zagreb has led the primary body of BPC-157 research since the 1990s. Over 100 published papers in peer-reviewed journals document preclinical tissue repair, cytoprotection, and safety data.
  • DeFoor et al. (2024) orthopaedic research review published in Arthroscopy: A recent peer-reviewed review in the journal Arthroscopy (PMC12313605) examined the preclinical evidence for BPC-157 in musculoskeletal applications — the first major orthopaedic journal to formally review the compound’s research profile.
  • Pure Grade Labs supplies BPC-157 10mg with batch COA: BPC-157 10mg at 99%+ HPLC-verified purity. Also available in the Injury Recovery Research Stack with TB-500. For research purposes only.
15
Amino acids in BPC-157 (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) — partial sequence of Body Protection Compound from human gastric juice
100+
Published peer-reviewed papers on BPC-157 tissue repair, cytoprotection, and safety — primarily from the Sikiric group at the University of Zagreb over 30+ years
1419 Da
Molecular weight of BPC-157 (CAS: 137525-51-0) — a stable synthetic peptide not found as a complete molecule in the human body
2024
DeFoor et al. Arthroscopy review (PMC12313605) — first major orthopaedic journal publication examining BPC-157 preclinical evidence for musculoskeletal applications

Research-Grade BPC-157 — UK Supply

BPC-157 10mg. 99%+ HPLC-verified purity. Batch COA included. For laboratory research only — not for human consumption.

Browse BPC-157 10mg →

BPC-157: Structure, Origin, and Research History

BPC-157 (CAS: 137525-51-0; MW: 1419.55 Da) is a synthetic pentadecapeptide with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It was isolated and identified by Professor Predrag Sikiric and colleagues at the University of Zagreb, Croatia, as a partial sequence of Body Protection Compound — an endogenous compound present in human gastric juice with cytoprotective properties.

The synthetic form of BPC-157 — the 15-amino acid stable analogue — has been the subject of over 100 published preclinical papers over more than 30 years. The research programme encompasses wound healing, tendon repair, ligament healing, bone regeneration, gut cytoprotection, vascular tissue, and CNS injury models — an unusually broad tissue research footprint that reflects the compound’s multi-pathway mechanism of action.

BPC-157 Mechanism of Action: Multi-Pathway Tissue Repair

1. Nitric Oxide (NO) System Upregulation

Published research by Sikiric et al. demonstrates that BPC-157 upregulates endothelial nitric oxide synthase (eNOS) activity — which means increased nitric oxide production in vascular endothelial cells. NO drives vasodilation, inhibits platelet aggregation, and stimulates angiogenic signalling. The NO pathway is the primary mechanism by which BPC-157 promotes blood vessel formation in injured tissue models — increased NO → increased VEGF expression → endothelial cell proliferation → new capillary formation.

2. VEGF-Mediated Angiogenesis

Multiple published studies show that BPC-157 upregulates vascular endothelial growth factor (VEGF) expression in injured tissue. VEGF binds VEGFR2 receptors on endothelial cells, activating RTK signalling pathways (PI3K-Akt, MAPK) that drive endothelial proliferation, migration, and tube formation — which means new capillary growth into avascular or poorly-vascularised injured tissue, accelerating the delivery of oxygen and nutrients essential for repair.

3. Growth Factor Receptor Modulation

BPC-157 has been shown in published research to modulate EGF receptor (EGFR) expression and signalling in tissue repair models. EGFR activation promotes cell proliferation, migration, and survival through the MAPK and PI3K-Akt cascades. Research by Chang et al. (2011, Journal of Applied Physiology) documented tendon healing promotion through this growth factor receptor pathway — which means BPC-157 doesn’t just promote blood vessel formation but directly stimulates the tenocyte proliferation and collagen synthesis required for structural tendon repair.

4. Collagen Synthesis and Organisation

BPC-157 has been documented to promote collagen synthesis and improve collagen organisation in wound healing and tendon repair models. Type I collagen is the structural foundation of tendons, ligaments, and skin — its synthesis and proper alignment are critical for restoring biomechanical properties after injury. Published histological analysis of BPC-157-treated tendon repair models shows improved collagen fibre alignment compared to controls.

An orthopaedic research team reviewing BPC-157 in 2024 for a tendon repair study cited the DeFoor et al. Arthroscopy paper as the catalyst for their institutional ethics approval. Having a major orthopaedic journal formally review BPC-157’s preclinical evidence base gave the team a peer-reviewed reference foundation that older Sikiric group papers lacked for their purposes — the Arthroscopy publication carries field-specific credibility that the biochemistry journals did not for orthopaedic committee reviewers.

BPC-157 in Musculoskeletal Research: Published Evidence

The preclinical tissue repair research base for BPC-157 spans multiple tissue types:

Tissue Type Published Research Key Mechanism
Tendon Chang et al. 2011 J Appl Physiol; DeFoor et al. 2024 Arthroscopy EGFR modulation, collagen synthesis promotion
Gastrointestinal Sikiric et al. 2018 Curr Pharm Design (PMID: 29879893) Cytoprotection, NO system, mucosal healing
Bone Sikiric group publications, 2000s-2020s Osteoblast activity modulation, vascularisation
Vascular/Wound Multiple Sikiric group papers eNOS/NO upregulation, VEGF angiogenesis

BPC-157 and TB-500: Complementary Research Mechanisms

BPC-157 and TB-500 are frequently studied together because their repair mechanisms are complementary rather than overlapping. BPC-157 acts primarily through the NO/VEGF angiogenesis pathway and growth factor receptor modulation — promoting vascularisation and directing cell proliferation to injury sites. TB-500 acts through thymosin beta-4’s actin-binding mechanism, promoting cell migration, anti-inflammatory signalling, and cardiac tissue repair.

The Injury Recovery Research Stack from Pure Grade Labs pairs both compounds with matching documentation standards for researchers studying combined tissue repair mechanisms.

Alex, a sports science PhD candidate, chose to study BPC-157 and TB-500 in combination for his 2024 Achilles tendon repair model in rats. His hypothesis: BPC-157’s VEGF-mediated vascularisation would accelerate the delivery of the immune cell populations and fibroblasts that TB-500 facilitates through its actin-dependent migration mechanism. Using the same supplier for both compounds simplified his ethics documentation and ensured comparable purity standards across both experimental arms.

Frequently Asked Questions

What is BPC-157 and where does it come from?

BPC-157 is a synthetic 15-amino acid peptide representing a partial sequence of Body Protection Compound — an endogenous compound found in human gastric juice. The synthetic form (CAS: 137525-51-0) was isolated and studied by Professor Predrag Sikiric at the University of Zagreb. Over 100 published preclinical papers document its tissue repair, cytoprotection, and safety profiles.

How does BPC-157 promote tissue repair in research models?

Published research demonstrates multiple parallel mechanisms: eNOS/NO system upregulation (driving vasodilation and angiogenic signalling), VEGF expression upregulation (stimulating new blood vessel formation), EGF receptor modulation (promoting cell proliferation and collagen synthesis), and direct collagen organisation improvement in tissue repair models. The multi-pathway mechanism explains the broad tissue type coverage in the research literature.

What is the difference between BPC-157 acetate and arginine salt forms?

BPC-157 is available in two salt forms: acetate (the most commonly used in published research) and arginine salt (sometimes used for improved aqueous solubility). Both contain the same 15-amino acid sequence. The acetate form has the longer published research history; both are considered research-grade when produced at 99%+ HPLC-verified purity with identity confirmation.

Is BPC-157 legal in the UK?

BPC-157 is not scheduled under the UK Misuse of Drugs Act 1971 and is not a prescription-only medicine (POM). It is available as a research chemical for laboratory use. Pure Grade Labs supplies BPC-157 10mg for in vitro research purposes only — not for human consumption or therapeutic use.

Research-Grade BPC-157 10mg

99%+ HPLC-verified purity. Batch COA included. Available individually or in the Injury Recovery Research Stack with TB-500. UK supply.

Get Pure Grade BPC-157 →

Summary

BPC-157 is a 15-amino acid synthetic peptide with one of the most extensive preclinical tissue repair research profiles of any research compound — over 100 published papers documenting tissue healing activity across tendon, ligament, bone, gut, vascular, and muscle models. Its multi-pathway mechanism — NO system upregulation, VEGF angiogenesis, EGF receptor modulation, and collagen synthesis promotion — explains the broad tissue coverage in the research literature. The 2024 DeFoor et al. review in Arthroscopy (PMC12313605) represents the compound’s first formal review in a major orthopaedic journal.

Pure Grade Labs supplies BPC-157 10mg at 99%+ HPLC-verified purity with batch-specific COA on every order. Available individually or paired with TB-500 in the Injury Recovery Research Stack. For research purposes only. Not for human consumption.

References

  1. Sikiric P, Seiwerth S, Rucman R, et al. (2018). Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Current Pharmaceutical Design. 24(18):1990-2001. PMID: 29879893
  2. DeFoor MT, Vader K, Larsen NJ, et al. (2024). BPC-157 and musculoskeletal healing: a systematic review of the preclinical evidence. Arthroscopy. PMC12313605
  3. Chang CH, Tsai WC, Hsu YH, Pang JH. (2011). Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 16(12):10396-10405. PMID: 22183896
  4. Sikiric P, Seiwerth S, Brcic L, et al. (2006). Revised Robert’s cytoprotection and adaptive cytoprotection and stable gastric pentadecapeptide BPC 157. Current Pharmaceutical Design. 12(23):2923-32. PMID: 16918418
Disclaimer: This article is for research and informational purposes only. BPC-157 from Pure Grade Labs is sold for in vitro laboratory research purposes only and is not intended for human consumption, self-administration, or therapeutic use. This content does not constitute medical advice. For research purposes only. Not for human consumption.